ALKS
Alkermes plc. · Healthcare · Market cap $7.3B
Insiders sold $3.8M net in the last 90 days ·4 sellers, 0 buyers· 6 of 7 sales under Rule 10b5-1 plans· latest Form 4 filed Oct 2, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$10.3M
reported sales (SEC code S)
Unique Insiders
7
in the rolling window
Latest filing
Oct 9, 2026
Gaffin David Joseph
Alkermes plc. (ALKS) has 58 SEC Form 4 filings (120 transaction rows) in the rolling window, disclosed by 7 distinct insiders. Most recent filing: Oct 9, 2026.
Inside the rolling window, 7 insiders at Alkermes plc. reported no open-market purchases and 29 open-market sales totaling $10.3M. The most active filer is EVP R&D, Chief Medical Officer Hopkinson Craig C. with 13 filings. Insiders have net sold $5.9M over the trailing 6 months. The most recent open-market filing is a sale of 2,034 shares by EVP, CLO, Alkermes, Inc. Gaffin David Joseph, dated Oct 2, 2026, worth $83K.
- Industry:Drug Manufacturers - Specialty & Generic
- CEO:Blair Jackson
- Employees:2,050
- HQ:Dublin, DU, IE
- IPO:1991-07-16
| Source | |||||||
|---|---|---|---|---|---|---|---|
| EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $83K | Oct 2 | +4.1% | SEC ↗ | |
| EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $98K | Sep 3 | -7.3% | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $423K | Sep 1 | -7.9% | SEC ↗ | |
Nichols Christian ToddFirst in 6 months | SVP, Chief Commercial Officer | Sale | 7,576 | $373K | Aug 17 | -12.8% | SEC ↗ |
snyderman nancy lynn MDFirst filing | Director | Sale | 44,472 | $2.2M | Aug 3 | -12.2% | SEC ↗ |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $437K | Aug 3 | -12.2% | SEC ↗ | |
| EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $99K | Aug 3 | -12.2% | SEC ↗ | |
| EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $110K | Jul 6 | -21.1% | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $464K | Jul 1 | -15.9% | SEC ↗ | |
Wright Christopher IFirst filing | Director | Sale | 2,000 | $90K | Jun 13 | — | SEC ↗ |
| EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $88K | Jun 4 | — | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $375K | Jun 1 | — | SEC ↗ | |
| VP, Finance (Interim PAO) | Sale | 16,217 | $687K | May 29 | — | SEC ↗ | |
| EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $68K | May 5 | — | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $301K | May 2 | — | SEC ↗ | |
| EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $70K | Apr 6 | — | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $320K | Apr 1 | — | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $267K | Mar 4 | — | SEC ↗ | |
Gaffin David JosephFirst filing | EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $60K | Mar 4 | — | SEC ↗ |
Gaffin David JosephFirst filing | EVP, CLO, Alkermes, Inc. | Sale | 2,034 | $61K | Mar 4 | — | SEC ↗ |
Nichols Christian ToddFirst filing | SVP, Chief Commercial Officer | Sale | 6,000 | $180K | Mar 4 | — | SEC ↗ |
Parisi Samuel JosephFirst filing | VP, Finance (Interim PAO) | Sale | 6,890 | $202K | Mar 4 | — | SEC ↗ |
Cooke ShaneFirst filing | Director | Sale | 61,200 | $2.1M | Feb 2 | — | SEC ↗ |
| EVP R&D, Chief Medical Officer | Sale | 9,000 | $305K | Feb 2 | — | SEC ↗ | |
| EVP R&D, Chief Medical Officer | Sale | 5,000 | $150K | Jan 8 | — | SEC ↗ |
Earnings: last 7 quarters
Congress trading ALKS 1 all-time
- DRep. Gilbert Ray CisnerosPurchase$15,001 - $50,0002026-07-29
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does ALKS have?
Alkermes plc. (ALKS) has 58 SEC Form 4 filings (120 transaction rows) in the rolling 365-day window, disclosed by 7 distinct insiders. Most recent filing: Oct 9, 2026.
When was the most recent SEC Form 4 filing for ALKS?
The most recent Form 4 filing for ALKS on Tracefour is dated Oct 9, 2026.
Who is the most active insider at ALKS?
The most active SEC Form 4 filer at ALKS in the rolling window is EVP R&D, Chief Medical Officer Hopkinson Craig C., with 13 filings.
What is the net insider flow at ALKS over the last 6 months?
Over the trailing 180 days, insiders at ALKS have net sold $5.9M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at ALKS in the current window?
Inside the rolling window, insiders at ALKS bought $0 and sold $10.3M based on SEC Form 4 filings.
Can I get alerts for ALKS insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Alkermes plc. (ALKS). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Alkermes plc. is in the Healthcare sector.